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Abstract: The use of intra-articular viscosupplementation in the nonoperative management 
of patients with osteoarthritis has become quite popular. Recent clinical data have demonstrated 
that the anti-inflammatory and chondroprotective actions of hyaluronic acid viscosupplementation 
reduce pain while improving patient function. We review the basic science and development 
of viscosupplementation and discuss the mounting evidence in support of the efficacy and 
safety profile of hylan G-F 20. Recent evidence suggesting a disease-modifying effect of hylan 
G-F 20 is also assessed. Furthermore, although the primary focus of this article is on treatment 
of osteoarthritis of the knee, we also discuss the use of viscosupplementation in other joints, 
such as the hip, ankle, and shoulder.
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Introduction
Osteoarthritis is the most common joint disorder in the aging population.1 In the United 
States alone, recent projections report that by the year 2030 the disease will affect 
almost 63 million Americans. The Centers for Disease Control and Prevention has 
estimated that the annual direct and indirect costs associated with osteoarthritis and 
other rheumatologic conditions total approximately US$86.2 billion.2 Osteoarthritis 
is also a clinically significant cause of disability. In a recent survey of all causes of 
lost productive time in the US workforce, Stewart et al3 discovered that arthritis was 
second only to low back pain as a specific cause of lost work and reduced performance 
at work.
Although surgical treatment of osteoarthritis can reduce pain and improve joint 
mobility and function, the operative management of osteoarthritis is associated with 
significant cost and potential morbidity. Furthermore, not all patients are candidates 
for surgical intervention, and they may wish to delay or avoid it if possible. 
There are several nonsurgical treatment options for symptomatic osteoarthritis 
including weight loss, exercise, activity modification, physical therapy, bracing, 
wedged shoe insoles, walking aids, nonsteroidal anti-inflammatory drugs (NSAIDS), 
and intra-articular injections of corticosteroids.4,5 In September 2000, the American 
College of Rheumatology guidelines for the treatment of osteoarthritis of the knee 
recommended that one treatment option to be considered is the use of intra-articular 
injections of hyaluronic acid for the relief of osteoarthritic pain.5 Since then, hyaluronic 
acid viscosupplementation has become one of the more popular nonoperative treatment 
options for symptomatic osteoarthritis.6–8 More recently, in 2008, the Osteoarthritis Journal of Pain Research 2009:2 88
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Research Society International (OARSI) cited intra-articular 
hyaluronic acid as a useful therapeutic modality, that has 
delayed onset, but prolonged duration of symptomatic 
benefit, in treating patients with osteoarthritis of the knee 
or hip.4 In addition, although marketed as analgesics, 
viscosupplements have been postulated to have potential 
chondroprotective effects as well.9
We reviewed the development, indications, clinical 
efficacy, and safety profile of hylan G-F 20 (Synvisc®; 
Genzyme Biosurgery, Cambridge, MA, USA) primarily 
in the management of osteoarthritis of the knee; however, 
we will also briefly discuss recent evidence that suggests 
the efficacy of hylan G-F 20 in other joints, such as the hip 
and ankle.
Basic science of hyaluronic acid
Hyaluronic acid (HA), also known as hyaluronan or hyaluro-
nate, is a high-molecular-weight glycosaminoglycan made 
up of repeating disaccharide units of N-acetyl-glucosamine 
and glucoronic acid.10 The average molecular weight of 
synovial fluid HA is 5 to 7 × 106 Da. Type B synoviocytes 
and fibroblasts synthesize HA and secrete it into the joint 
space. HA molecules occupy a large spheroidal space while 
in their fully hydrated state. Therefore, the viscoelasticity 
and flow characteristics of synovial fluid are intimately tied 
to its HA content.
Synovial fluid viscoelasticity is essential for normal 
joint function. Hyaluronic acid has both viscous and elastic 
properties, and the degree to which either predominates 
depends on distinct loading conditions. This allows synovial 
fluid the unique capacity to function differently depending 
on the amount of shear force applied.11 For example, in the 
presence of low shear forces, typically with slow joint 
mechanics, HA molecules exhibit high viscosity with reduced 
elasticity. With increased rates of joint motion (high shear), 
this reverses as the synovial fluid becomes more elastic 
and absorbs energy more efficiently.121 Therefore, synovial 
fluid acts as a lubricant during slow movements and as a 
shock absorber during rapid movements. Because of this 
energy dependent viscoelasticity, HA has been termed 
“pseudoplastic.”10
The normal adult knee contains approximately 2 mL 
of synovial fluid, with a HA concentration of 2.5 to 
4.0 mg/mL.13 In the arthritic joint, the concentration and 
molecular weight of HA are decreased by 33% to 50% 
because of dilution from inflammatory effusion, abnormal 
synoviocytes, and molecular fragmentation.14,15 These 
alterations lead to dramatically poorer viscous and elastic 
properties and, thus, distorted joint mechanics. Decreased 
lubrication leads to increased stress on the already diseased 
cartilage, which further disrupts the collagen network and the 
integrity of the chondral surface. The loss of barrier integrity 
also adversely affects cartilage nutrition and waste removal. 
Finally, fragmented low-molecular-weight HA may actually 
have a proinflammatory effect.16
Intra-articular kinetic studies argue against improved 
biomechanics as the major explanation for viscosupplementa-
tion efficacy. Fraser et al17 developed a HA assay in a sheep 
model. They reported the mean half-life of [3H] acetyl-labeled 
hyaluronic acid in normal joints was 20.8 hours, compared 
with 11.5 hours in acutely inflamed joints. Extrapolating 
these figures and using them as a rough guide to the kinetics 
of the human osteoarthritic joint, the mechanism of action of 
viscosupplementation must be more than the simple replen-
ishment of degraded HA. This has led to further research into 
other significant functions of HA within the joint. Recent 
studies have suggested that HA exerts anti-inflammatory, 
analgesic, and possibly chondroprotective effects in the 
articular cartilage and joint synovium.8,12,18
Hyaluronic acid exerts its anti-inflammatory effect 
within the joint space by influencing a variety of leukocyte 
functions both in vivo and in vitro. These include inhibition 
of migration, chemotaxis, phagocytosis, adherence, and 
proliferation.12,19–21 Tamoto et al21 demonstrated in an animal 
model that HA affects leukocyte signal transduction via 
cell-surface receptors, which are dependent on the size of 
the HA molecule. Furthermore, intra-articular injection of 
HA reduces the concentration of inflammatory mediators, 
such as prostaglandins, fibronectin, and cyclic AMP in the 
synovial fluid of patients with arthritis.22,23 Tobetto et al24 used 
in vitro assays to demonstrate that HA can affect the release 
of arachidonic acid from human synovial fibroblasts.
Although the anti-inflammatory properties of HA may 
explain some of its analgesic properties, direct analgesic 
activity of intra-articular HA injection has been demonstrated 
in recent animal models. This seems to be mediated both 
directly through inhibition of nociceptors and indirectly 
via decreasing the synthesis of or binding to bradykinin, 
substance P, and other hyperalgesic compounds.25–28
Of even greater significance are the results of basic science 
studies demonstrating various positive effects of HA on both 
synoviocyte and chondrocyte metabolism.29 Ghosh25 demon-
strated de novo HA biosynthesis by fibroblasts upon in vitro 
exposure to exogenous HA. This effect was dependent on both 
concentration and molecular weight of exogenous HA. In this 
same study, the authors also demonstrated that high molecular Journal of Pain Research 2009:2 89
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weight, cross-linked derivatives of HA actually provided 
a protective effect on chondrocytes exposed to leukocyte 
proteinases, IL-1, or oxygen-derived free radicals. Again, 
this effect was viscosity dependent, with higher molecular 
weight HA providing superior protection compared with 
lower viscosity formulations.
Development of viscosupplements
Balazs and associates10 pioneered the concept of visco-
supplementation in the 1960s. This concept was based on 
extensive research into joint fluid flow and HA itself. They 
believed an ideal viscosupplement should meet 4 specific 
criteria: 1) permeability to metabolites and macromolecules, 
2) non-immunogenic, 3) similar molecular weight to native 
synovial fluid, and 4) a long half-life.
The first clinical use of viscosupplementation did not 
occur until the late 1980s when Hyalgan® (Fidia, Italy) and 
Artz® (Seikagaku, Japan) were placed on the foreign market 
for use in human arthritic knees. Viscosupplementation with 
intra-articular (knee) HA was approved by the Food and Drug 
Administration (FDA) in 1997. The FDA currently does not 
approve viscosupplementation therapy for use in joints other 
than the knee. However, several trials, to be discussed later, 
have shown that it may be useful in treating osteoarthritis 
pain in other joints such as the hip, ankle, and shoulder.
The aforementioned HA formulations required multiple 
injections because they were relatively lower in molecular 
weight. To address this issue of shortened half-life, cross-
linked hyaluronans, called hylans, were developed. Hylans 
have been reported to have improved viscoelastic properties 
and an increased duration within the joint, as a function of 
cross-linking.30 Hylan G-F 20 was the first, and remains 
the only, cross-linked HA available in the United States.2 
Hylan G-F 20 consists of a combination of the fluid and 
gel forms at a 4:1 ratio. Its molecular weight is 6 × 106 Da, 
similar to that of HA in a healthy joint. There are four other 
HA formulations approved for use in the United States: 
Hyalgan® (Sanofi-Sythelabo Inc, New York, NY, USA), 
Supartz® (Seikagaku Corp, Tokyo, Japan), Orthovisc® 
(Anika Therapeutics Inc, Woburn, MA, USA), and Euflexxa® 
(Ferring Pharmaceuticals Inc, Suffern, NY, USA) (Table 1). 
The few published head-to-head clinical trials in humans have 
not demonstrated a clear efficacy advantage of one product 
over another.31 However, some published studies suggest that 
higher-molecular-weight HA is more efficacious.6,32
Clinical efficacy
The efficacy of hyaluronic preparations has been published 
in numerous clinical outcome studies.6,33–42 The first human 
clinical trial of intra-articular HA in the treatment of arthritis 
was published by Peyron and Balazs33 in 1974. In this study, 
14 patients were randomly assigned to either treatment or 
placebo groups. At 4-month follow up, the treatment group 
reported some improvement in joint symptoms. Since 
then, numerous large, multicenter, randomized, blinded, 
placebo-controlled studies have been performed.38,40,42–45 
The reported benefits, however, have been variable. Wang 
et al6 performed a meta-analysis to determine the effects of 
intra-articular injection of HA on knee osteoarthritis and to 
elucidate the therapeutic efficacy and safety of the procedure. 
They evaluated 20 randomized controlled trials that com-
pared both cross-linked (hylan G-F 20) and noncross-linked 
hyaluronates with placebo. All trials used validated outcome 
measures and safety was assessed by the relative risk of an 
adverse event. The authors reported that both cross-linked 
(hylan G-F 20) and noncross-linked hyaluronates do indeed 
have a therapeutic effect in patients with osteoarthritis of the 
knee when compared with placebo. They found significant 
improvements in pain on activity, pain at rest, and function. 
Furthermore, trials that involved hylan G-F 20 showed 
much greater pooled estimates of efficacy than did the trials 
involving non-cross-linked hyaluronates. The most recent 
Table 1 Commercially available viscosupplements





Proven duration  
of action (weeks)
Dosing regimen Approximate 
cost (1 course)
Synvisc 60 (cross-linked) 8 26 3-weekly injections $589
Euflexxa 24–36 10 12 3-weekly injections $437
Hyalgan 5.0–7.3 10 8.5 (3 injections) 
26 (5 injections)
3- to 5-weekly injections $524
Supartz 6.2–11.7 10 14 (3 injections) 
26 (5 injections)
3- to 5-weekly injections $533
Orthovisc 10 15 22 3-weekly injections $543Journal of Pain Research 2009:2 90
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meta-analysis from the Cochrane database also confirmed 
the overall efficacy of all HA products.35 Bellamy and 
colleagues identified 76 randomized placebo-controlled trials 
that fulfilled strict methodology and study design criteria. 
Based on their careful analysis of the literature, the authors 
concluded that viscosupplementation is an effective treatment 
for osteoarthritis of the knee with favorable effects on pain, 
function, and patient global assessment, especially during 
the 5- to 13-week postinjection period.
In the specific case of hylan G-F 20, most studies 
report significant improvements in pain and physical 
functioning in patients followed for up to 3 months to a 
year (Table 2). However, a few trials demonstrate simi-
lar outcomes between hylan G-F 20 and intra-articular 
controls. Overall, clinically meaningful improvements with 
hylan G-F 20 have been demonstrated by pain improve-
ments from baseline of 33% to 80% compared with 21% 
to 26% with placebo.46 We have identified 4 randomized, 
placebo-controlled trials investigating the use of 3 weekly 
intra-articular injections of hylan G-F 20 for the treatment 
of knee osteoarthritis.38,40,44,45 In a 26-week study, Wobig 
et al38 reported significant improvements on visual analog 
testing versus placebo for pain during weight-bearing, 
pain at rest, pain during most painful knee movement, 
and treatment success. At the end of the 26 weeks, signifi-
cantly more hylan G-F 20-treated patients versus placebo-
treated patients were symptom free and required less use 
of NSAIDS or steroid as rescue therapy. Scale et al44 
published similar significant improvements in activity, 
weight-bearing pain, most painful knee movement, and 
investigator and patient global evaluations in their 12-week 
study of 80 patients treated with two and three injections of 
hylan G-F 20. Another 12-week study (n = 165) indicated 
significant improvements with hylan G-F 20 versus placebo 
on the WOMAC A (pain walking on flat surface, pain while 
sitting or lying) and WOMAC C total scores of the West-
ern Ontario McMasters University Osteoarthritis Index.45 
Finally, Karlsson et al40 did not find any difference in clini-
cal efficacy between patients treated with hylan G-F 20 or 
placebo group at 26 or 52 weeks. However, pooled data for 
all HA treatment arms revealed significantly longer duration 
of improvement when compared with placebo.
Open-labeled, prospective, comparative, and retrospective 
studies have also shown improvement of symptoms of knee 
osteoarthritis after treatment with hylan G-F 20.30,32,39,41,47–50 
For example, Waddell et al41 published treatment results 
in 1047 patients treated with intra-articular hylan G-F 20 
(3 weekly injections) for osteoarthritis knee pain. They 
reported decreased pain, improved mobility, and decreased 
need for rescue pain medication in most of the treated knees 
(89%). Raman et al51 evaluated the functional outcome of 
almost 200 patients treated with hylan G-F 20 at pre-injection, 
6 weeks, 3, 6, and 12 months. The authors noted an 
improvement in WOMAC, Oxford knee and EuroQol EQ-5D 
scores at each time point. In addition, a 2008 multi-center 
study conducted by Huskin and colleagues47 demonstrated 
that hylan G-F 20 provided effective pain relief and improved 
stiffness and physical function in patients will mild to moderate 
osteoarthritis presenting with persistent osteoarthritic pain 
4 to 12 weeks after arthroscopic meniscectomy.
Table 2 Prospective, randomized, placebo-controlled trials of hylan G-F 20 for treatment of osteoarthritis of the knee
Study N Intervention Duration of study Outcome measures Outcomes
Scale et al44 80 Study 1: hylan G-F 20,  
2 injections vs placebo  
Study 2: hylan G-F 20,  
3 injections vs placebo
12 weeks VAS, activity level, physician 
global assessment
Significant improvement in VAS, 
activity level, most painful knee 
improvement, physician global 
assessment in the treatment 
group compared with placebo at 
12 weeks
wobig et al38 110 Hylan G-F 20, 3 injections vs  
placebo
26 weeks VAS pain scale,   VAS 
functional scale
Significant improvement in all 
parameters in treatment group; 
less use of “rescue therapy” in 
treatment group
Dickson et al45 165 Hylan G-F 20 vs diclofenac vs 
arthrocentesis plus oral  
placebo
12 weeks wOMAC A pain Significant improvement in 
wOMAC A pain categories
Karlsson et al40 Hylan G-F 20, 3 injections vs 
placebo
52 weeks VAS, Kaplan-Meier Survival, 
SF-36, WOMAC, Lequesne 
algofunctional index
No difference in outcome 
between treatment group and 
placebo at 52 weeks
Abbreviations:   VAS, visual analog scale;   WOMAC,   Western Ontario McMasters University Osteoarthritis Index.Journal of Pain Research 2009:2 91
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Increasing attention has shifted toward comparing 
hylan G-F 20 with other nonoperative knee osteoarthritis 
treatment strategies. These include NSAIDs and intra-
articular steroid injections. Several randomized controlled 
trials comparing hylan G-F 20 viscosupplementation with 
NSAIDs have reported that the benefit obtained with intra-
articular hylan G-F 20 was similar to or greater than that 
observed with NSAIDs, with fewer gastrointestinal side 
effects.37,46,52 In a multicenter Canadian trial, Adams and 
colleagues37 compared three treatment groups: oral NSAIDs 
alone, hylan G-F 20 treatment (3 weekly injections), and a 
combination of oral NSAIDs and hylan G-F 20 treatment. 
At 6 months, both the hylan G-F 20 only and the combined 
NSAID and hylan G-F 20 groups were statistically 
superior to the NSAID only group. These findings are 
further supported by the previously mentioned Cochrane 
review, which reported that when hylan G-F 20 was added 
to pre-existing NSAID therapy, combination therapy was 
associated with greater improvement in pain and joint 
function than use of NSAIDs alone.35
Studies comparing intra-articular therapy with corti-
costeroids and hylan G-F 20 have demonstrated that both 
treatments are effective in reducing knee osteoarthritis 
symptoms; however, viscosupplementation has a longer 
duration of action while corticosteroids have a more rapid 
onset of action.53 Two recent prospective trials have compared 
intra-articular hylan G-F 20 to intra-articular corticosteroids. 
Leopold et al54 prospectively compared 2 treatment arms. The 
first groups received 3-weekly injections of hylan G-F 20, 
and the second group received 1 injection of intra-articular 
betamethasone. At the 6-month follow-up, both groups 
improved. However, there was no statistically significant 
difference between the two groups for VAS and WOMAC 
scores, or the Knee Society Scoring System. Caborn and 
associates53 also studied similar cohorts. In their comparison 
of intra-articular hylan G-F 20 (3 weekly injections) and 
intra-articular triamcinolone (1 isolated injection) they found 
that although the maximal benefit of corticosteroids appeared 
more rapidly (week 2), pain reduction and functional improve-
ment were significantly superior (P  0.01 and P  0.001, 
respectively) with hylan G-F 20 viscosupplementation at the 
3- to 6-month follow up periods.
Juni et al55 and others also explored the effect of the 
increased molecular weight of hylan G-F 20. In a randomized, 
controlled, blinded study, Karlsson et al40 evaluated 3 parallel 
cohorts of patients with knee osteoarthritis. The patients in 
each group received 1 of 3 treatments: 3-weekly injections of 
sodium hyaluronate (Artzal®), 3-weekly injections of hylan 
G-F 20 (Synvisc®), or placebo. No significant differences 
were noted between those treated with low or high molecular 
weight preparations. Kotevoglu et al31 also examined the 
efficacy of different molecular weight hyaluronan solutions. 
Their 6-month follow-up data revealed no statistically 
significant difference in clinical efficacy between hylan 
G-F 20 and sodium hyaluronate. Wobig et al32 treated patients 
with 3 weekly injections of either hylan G-F 20 or sodium 
hyaluronate. However, in their group of 70 patients, the 
authors observed that patients treated with hylan G-F 20 had 
superior outcomes to those treated with the low molecular 
weight viscosupplement with regards to pain and physician 
assessment at 3-month follow-up. Finally, in a 2005 review, 
Goldberg and Buckwalter56 affirmed that, to date, no 
substantive clinical evidence has been put forth to suggest 
that differences in the molecular weight of currently available 
viscosupplements have any impact on clinical efficacy.
Multiple studies of intra-articular HA have confirmed 
the benefit of treatment with more than one course of hylan 
G-F 20. In a prospective open-label study, Waddell et al57 
evaluated the efficacy and tolerability of a second course of 
hylan G-F 20 for the treatment of osteoarthritic knee pain over 
a 12-month period in patients who previously experienced a 
beneficial initial course of therapy. Most patients experienced 
continued pain relief as all efficacy parameters significantly 
improved (P  0.001) from baseline at weeks 1, 2, 4, 8, 12, 
26, and 52. Furthermore, Raynauld and colleagues,58 in a 
randomized controlled trial, reported that a second course 
of therapy with hylan G-F 20 was just as effective as the 
first course in a study comparing intra-articular HA with 
appropriate care. They also demonstrated the safety of repeat 
treatment in that the incidence of local mild adverse events 
with hylan G-F 20 was not significantly higher than with 
a first course of therapy. This safety profile is also supported 
in a recent meta-analysis by Pagnano et al59 However, as we 
discuss later, the incidence of a rare severe acute inflamma-
tory reaction after repeated treatment may be slightly higher 
with the use of hylans.60
Clinical safety
The safety profile HA viscosupplementation has been well 
established over its 20 years of clinical use. In fact, no 
viscosupplement product has been withdrawn because of 
safety concerns.61 Intra-articular HA and hylan products are 
generally well tolerated with low incidence of local adverse 
events.44 The overall incidence of adverse events has been 
reported to be approximately 1% to 4% per injection.13,30,41,62 
In the specific case of hylan G-F 20, the incidence is closer Journal of Pain Research 2009:2 92
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to 0% to 1%.38,45 However, in one small retrospective series, 
clinically significant local inflammatory reactions were noted 
in 27% of the 22 patients (11% of injections) that received 
hylan G-F 20.63
Postmarketing surveillance for hylan G-F 20 (Synvisc®) 
has indicated that the most common adverse event is local 
reaction at the injection site, consisting of mild pain, swelling, 
or effusion, and warmth or redness, or both.38,64 Such injection 
site reactions are usually mild and self-limited, resolving 
with 1 to 3 days and generally respond to NSAIDs and 
local modalities. Other mild adverse effects that have been 
reported include postinjection itching, headaches, and calf 
pain.65,66 Furthermore, the incidence of adverse events with 
viscosupplementation is similar to that observed with other 
intra-articular procedures used to evaluate the efficacy of 
treatment for knee osteoarthritis. In controlled comparisons 
of Synvisc® and arthrocentesis or intra-articular saline 
injections involving 122 patients, there were no significant 
differences in the numbers or types of adverse events between 
treatment groups.53,61,67 Moreover, self-limited synovitis with 
corticosteroids has been reported in about 2% of cases.68
A number of US and international trials have established 
the safety of hylan G-F 20. The combined results of 7 clinical 
trials consisting of 511 subjects and 1711 injections revealed 
no serious adverse events.61 Furthermore, only 7% of 
subjects (2.3% injections) reported swelling and/or knee 
pain after injections. In a large, retrospective review of 
viscosupplementation with hylan G-F 20, local reactions 
occurred after 42 (2.7%) of 1537 injections and occurred 
in 28 (8.3%) of 336 patients overall.30 Seventy-nine percent 
of these reactions resolved without sequelae. Five patients 
had a total of nine reactions with sequelae, including 
residual swelling and intermittent pain. The incidence of 
adverse events was significantly related to the injection 
technique used: a medial approach to a partially bent knee 
was associated with 5.2% adverse events by injection, 
compared with1.5% with straight lateral injections. 
Interestingly, injection laterally has also been shown to 
have a higher incidence of intra-articular injection accuracy 
when compared with injection into the flexed knee using 
conventional arthroscopic portal approaches.69 Brockmeir 
and Schaffer12 postulated that adverse reactions are related 
more closely to the accuracy of intra-articular injection than 
to the substance itself.
Rare cases of crystalline induced arthropathy related to 
hylan G-F 20 have also have also been reported.70,71 The 
mechanisms underlying the development of pseudogout 
after HA injection remain unclear. What is clear is that this 
synovitis tends to occur after the second or third injection 
suggesting an immune mediated response. Furthermore, 
recurrence of the reaction has been noted in some particular 
patients, also suggesting that some individuals may be 
predisposed to these reactions. Therefore, clinicians should 
consider pseudogout as a possible, although rare, adverse 
effect when administering Synvisc®, especially in patients 
with radiographic evidence of calcium pycophosphate 
dihydrate (CPPD) crystals.70
Overall, hylan G-F 20 has a very good tolerability profile 
in clinical trials and practice. However, there is growing 
evidence to suggest that hylan G-F 20 in particular may be 
associated with a specific adverse event termed pseudosepsis 
or severe acute inflammatory reaction (SAIR).64 Pseudosepsis 
appears to be a distinct clinical reaction unrelated to the 
previously discussed minor adverse events. Its clinical 
presentation may be difficult to differentiate from a true 
septic knee or even pseudogout episode without joint fluid 
aspirate studies. The syndrome itself is characterized by 
the following: 1) severe pain occurring 1 to 3 days after 
an injection; 2) usually occurring after the first injection 
or treatment course (prior exposure); 3) highly cellular 
joint effusion without crystals or bacteria by culture; 
4) usually requires clinical intervention (NSAIDs, arthro-
centesis, or intra-articular steroid injection).61 Although 
severe, pseudosepsis seems to be a relatively rare occurrence 
after Synvisc® injection. In several case reports and retro-
spective studies pseudosepsis has been identified in a total 
of 22 patients, and, in 2 prospective studies, pseudosepsis 
occurred once in 213 injections in patients who received a 
second treatment of Synvisc® and once in 171 injections in 
patients who received an initial Synvisc® treatment.41,60,72,73
Naturally derived sodium hyaluronates, such as 
Hyalgan®, have not yet been linked with pseudosepsis, 
suggesting a possible connection between pseudosepsis and 
the chemical modification (covalent cross-linking) of the 
hyaluronan molecule used to manufacture Synvisc®. When 
it does occur, pseudosepsis characteristically is seen after 
previous exposure, prompting some investigators to postu-
late that the cause of pseudosepsis may be immune-based 
and possibly reflective of immunologic sensitization.64,74,75 
In a recent prospective study comparing joint aspirates from 
16 patients who presented with pseudosepsis after Synvisc® 
treatment with 20 joint aspirates from control patients with 
osteoarthritis, analysis was notably more consistent with 
a type 4(cell-mediated) hypersensitivity reaction than with an 
antibody-mediated reaction.71 Additional studies are required 
to elucidate the cause of pseudosepsis. Understanding the Journal of Pain Research 2009:2 93
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cause will enable the treating physician to identify patients at 
risk for this injection-related complication and to determine 
whether patients with a history of pseudosepsis can safely 
receive further viscosupplementation therapy.
Although the cause of local adverse events associated 
with Synvisc® injection is not clear, these events are typically 
mild-to-moderate in nature, resolve spontaneously or after 
treatment of symptoms, and do not result in any long-
term sequelae. Therefore, it is often difficult to clinically 
distinguish the symptoms of a reaction from the symptoms 
of osteoarthritis. Additionally, the types of usual local 
adverse events observed after viscosupplementation are not 
as potentially serious as the systemic adverse effects that 
may occur with NSAIDs or COX-2 inhibitors.76
Indications
The ideal candidate for intra-articular viscosupplementation 
is has yet to be clearly defined. Previous guidelines for the 
treatment of knee osteoarthritis recommend the use of HA 
only in patients who have not responded to nonpharmacologic 
therapies and simple analgesics, and after the unsuccessful 
trial of NSAIDs and selective COX-2 inhibitors.74,77 
However, given the cardiovascular, gastrointestinal, and renal 
side effects of selective and nonselective NSAIDs, the use of 
HA products earlier in the osteoarthritis treatment paradigm 
should be considered.79,80 Again, despite failure to identify the 
optimal cohort, there is evidence suggesting that the greatest 
potential benefit of HA would likely be among younger 
patients and those in the earlier stages of osteoarthritis. In the 
meta-analysis by Wang et al6 patients older than 65 and 
those with the most advanced stages of osteoarthritis were 
less likely to benefit from hylan G-F 20 therapy. Evanich 
et al49 also reported greater improvements in pain scores 
for patients with less severe radiographic disease compared 
with those having more severe disease with hylan G-F 20. 
Last, a short-term safety study of 4253 patients given hylan 
G-F 20 revealed that those patients who were most recently 
diagnosed with knee osteoarthritis were more likely to have 
an early benefit of therapy compared with those who had 
been diagnosed at a later time point in the disease course.50 
As a whole, these studies support the use of HA earlier in 
the osteoarthritis treatment regimen.
The most recent OARSI guidelines state that optimal 
management of patients with knee osteoarthritis requires a 
combination of nonpharmacological and pharmacological 
modalities of therapy.4 Physicians should therefore 
consider incorporating the use of HA or hylan G-F 20 into 
a comprehensive treatment program for knee osteoarthritis. 
The best evidence to support this idea are the studies 
conducted by Kahan et al81 and Raynauld et al39 demonstrat-
ing significant improvements in knee osteoarthritis symptoms 
when hylan G-F 20 was added to usual therapy for managing 
knee osteoarthritis. Hylan G-F 20 may also decrease the use 
of concomitant corticosteroids and NSAIDs when added to 
standard care for knee osteoarthritis.50 A few studies also 
indicate that the use of hylan G-F 20 may even delay the 
need for total knee replacement. For example, Waddell and 
colleagues82 demonstrated the ability of hylan G-F 20 to delay 
the need for total knee replacement by approximately 2 years 
in patients with grade IV osteoarthritis. Bell and associates83 
also showed that over a 30-month period, almost 60% of 
treated patients were able to delay knee replacement surgery 
after up to four courses of hylan G-F 20.
Finally, the dosing regimen can be as important as the 
timing of HA injections. Different dosing regimens of hylan 
G-F 20 can limit the availability of treatment and affect patient 
compliance. Yet the appropriate number, dose, and timing of 
hylan G-F 20 injections have yet to be determined. In a recent 
prospective, multi-center, randomized trial, Conrozier et al36 
evaluated the safety and efficacy of five dosing regimens of 
viscosupplementation with hylan G-F 20 in patients with 
symptomatic knee osteoarthritis: 1) a single injection of 6 mL, 
2) a single injection of 4 mL, 3) two injections of 4 mL 2 weeks 
apart, 4) 3 injections of 4 mL 1 week a part, or 5) 3 injections of 
2 mL 1 week apart. The treatment was well-tolerated overall, 
and there were no serious device-related adverse events. There 
was a statistically significant improvement from baseline at 
week 24 in all efficacy endpoints for all treatment regimens. 
However, the 1 × 6 mL, 3 × 4 mL, and 3 × 2 mL treatment 
groups showed the greater mean improvements in the patient-
rated knee osteoarthritis pain assessment VAS than the other 
groups. Another more recent randomized, placebo-controlled 
trial specifically compared a single, 6 mL, injection of hylan 
G-F 20 with placebo. A 2009 study by Chevalier and associ-
ates84 demonstrated that, in patients with knee osteoarthritis, 
a single 6 mL intra-articular injection of hylan G-F 20 is safe 
and effective in providing statistically significant, clinically 
relevant pain relief over 26 weeks, with a modest difference 
versus placebo. These findings suggest that a single-dose 
preparation (6 mL) may be as efficacious and as well-tolerated 
as the more commonly used 3 × 2 mL dosing.
Alternative uses  
for viscosupplementation
As previously mentioned, evidence in the literature 
has demonstrated the disease-modifying properties of Journal of Pain Research 2009:2 94
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viscosupplementation.56,85 Several preclinical animal studies 
have supported the hypothesis that exogenous HA reduces 
cartilage breakdown and promotes tissue repair.86–88 For 
example, Smith et al88 assessed the pathological changes 
in the synovium of a sheep model of osteoarthritis and 
evaluated the effects of two HA preparations on this 
pathology. Increased fibrosis and vascularity are hallmarks 
of pathological changes in synovium in this meniscectomy 
model of osteoarthritis. The authors demonstrated that intra-
articular treatment with Hyalgan® decreased aggregate score, 
vascularity and depth of fibrosis. HYADD 4-G (an amide 
derivative of HA) treatment also decreased vascularity, 
intimal hyperplasia and increased high-molecular weight 
HA synthesis by synovial fibroblasts. This provides a poten-
tial mechanism for improving joint mobility and function 
in osteoarthritis. Amiel et al86 used a rabbit model of 
osteoarthritis, anterior cruciate ligament transection (ACLT), 
to investigate the long-term effects of single and sequential 
courses of HA therapy on osteoarthritis progression. One or 
two courses of 5 weekly intra-articular injections of sodium 
hyaluronate (Hyalgan®) or placebo were administered to rabbits 
(N = 10 per group). Gross morphological and histomorphometric 
evaluations were performed on harvested knee joints following 
sacrifice at 26 weeks after surgery. All the rabbits exhibited the 
characteristic pathologic changes of osteoarthritis. However, 
rabbits that received one or two courses of HA injections showed 
less disease progression than rabbits treated with ACLT alone 
or with 10 vehicle injections. Interestingly, rabbits that received 
10 HA injections showed significantly less surface roughness of 
the femoral cartilage compared with rabbits treated with ACLT, 
5 HA injections, or 10 vehicle injections, and showed signifi-
cantly less surface roughness of the tibial plateau compared with 
all other treatment groups (P  0.05).
Clinical studies have also provided evidence for the 
disease-modifying potential of HA. A large multicenter, 
blinded, randomized study performed by Jubb and associates89 
found that treatment with 3 cycles of HA significantly 
reduced joint space loss at 1 year in the subset of patients with 
less severe osteoarthritis. Bagga et al90 examined the effect 
of intra-articular hylan GF-20 injections on synovial fluid 
HA concentration, viscosity, and elasticity over a 6-month 
period in patients with mild to moderate osteoarthritis of the 
knees. Sequential synovial fluid samples were available from 
32 of 60 subjects injected at baseline (15 men, 17 women; 
mean age 65 years) at 3 months post injection. The mean 
HA concentration had increased by 13% (P  0.0008), and 
the complex shear modulus had increased by 16% (P  0.03). 
Furthermore, at 6 months the mean HA concentration 
increased by 10%. These results suggest that one possible 
mechanism of action of viscosupplementation is to promote 
endogenous HA production. However, whether or not this 
HA viscosupplementation is truly chondroprotective and will 
actually alter the natural history of osteoarthritis remains to 
be answered. Nonetheless, this potential benefit has increased 
the off-label use of intra-articular HA injections.
The use of intra-articular HA therapy after arthroscopy 
may have a positive effect on postoperative pain and improve 
the efficacy of treatment secondary to aiding in the rapid 
restoration of the lubricating and protective HA layer.91 
In a prospective, randomized, controlled study of 80 patients, 
Hempfling8 evaluated the efficacy of HA injection 
immediately after knee arthroscopy for persistent knee pain. 
He found that compared with the control group, patients 
treated with HA injections after arthroscopy maintained 
significantly greater pain-relieving and functional benefits 
of this surgical procedure at 2-year follow-up.
A number of recent studies have also attempted to evaluate 
the efficacy of hylan G-F 20 in joints other than the knee. 
In those other joints, viscosupplementation has been studied 
more extensively in the hip in patients with osteoarthritis. 
In a single-center study, Vad et al92 demonstrated statistically 
significant improvement in 22 patients with mild to moderate 
hip osteoarthritis pain 1 year after receiving 3 injections of 
hylan G-F 20. The overall success rate was 89% (90.5% 
among patients with mild to moderate osteoarthritis and 
50% among patients with severe osteoarthritis). In a study 
conducted by Tikiz and colleagues,93 3 weekly injections 
of hylan G-F 20 were compared with the same regimen 
using a low molecular weight preparation in the treatment of 
patients with hip osteoarthritis. Both groups noted significant 
clinical improvement, with no difference noted between two 
compounds.84 Recently, Migliore and associates94 performed 
a prospective, observational, open study aimed to assess 
the efficacy and safety of hylan G-F 20 in a large cohort of 
patients with symptomatic hip osteoarthritis. Two hundred and 
fifty patients presenting with symptomatic hip osteoarthritis 
received one 2 mL intra-articular (IA) injection of hylan 
G-F 20 under ultrasound guidance. Patients were followed-up 
every 3 months for a total of 12 months. In addition to VAS, 
outcome measurements included Lequesne index scores, 
NSAID intake, and physician and patient global assessments 
scores. The authors observed statistically significant reduc-
tions in each of these outcome measures. No systemic, serious 
or severe side effects were observed.
Fewer injections of high-molecular-weight HA may 
be required in hip osteoarthritis versus knee osteoarthritis. Journal of Pain Research 2009:2 95
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Conrozier and associates95 retrospectively applied the 
Outcome Measures in Clinical Trials-Osteoarthritis Research 
Society International (OMERACT-OARSI) criteria to the 
results if a pilot study consisting of 56 patients with moderate 
to severe osteoarthritis of the hip who received 1 or 2 
injections of high-molecular-weight HA. They discovered 
that, at 90 days after injection therapy, 58.9% of patients 
met the OMERACT-OARSI response criteria. This observa-
tion supports the potential benefit of fewer injections of high-
molecular-weight HA in the setting of hip osteoarthritis.
The efficacy of HA viscosupplementation has also been 
demonstrated in the treatment of ankle, shoulder, and hand 
osteoarthritis.96–100 In a prospective, multi-center study, 
Witteveen et al99 evaluated the safety and efficacy of hylan 
G-F 20 in 55 patients with symptomatic ankle osteoarthritis. 
Patients received 1 mL × 2 ml intra-articular injection of 
hylan G-F 20, plus an optional, second injection if pain 
remained at baseline levels after 1, 2 or 3 months. The 
mean pain VAS score decreased from 68.0 mm (baseline) 
to 33.8 mm at 3 months (P  0.001), which was maintained 
to 6 months (34.2 mm, P  0.001). In a long-term prospec-
tive study, Luciani et al100 treated 21 patients with painful 
ankle osteoarthritis with 3-weekly injections of hylan G-F 20. 
Significant improvement of the baseline ankle osteoarthritis 
score was seen after 6 months. This improvement was main-
tained over time with no further changes at 12- and 18-month 
follow-up examinations.
In general, HA injection into the shoulder is well tolerated 
and evidence suggests that it may be effective in shoulder 
pain of various etiologies, including bursitis, glenohumeral 
osteoarthritis and rotator cuff tears. Among the strongest 
evidence is that which comes from a large, double-blind, 
randomized, saline-controlled study of HA injection for 
persistent shoulder pain.96 This study included 602 patients 
with shoulder pain of at least 6 months’ duration, caused by 
glenohumeral osteoarthritis, rotator cuff tear, or adhesive 
capsulitis. Patients who received 3- or 5-weekly HA injections 
experienced significant pain reduction compared to controls 
(P = 0.036 and P = 0.012, respectively). Patients whose 
shoulder pain was secondary to glenohumeral osteoarthritis 
experienced the majority of benefit. Furthermore, at 6 months 
pain reduction remained significant in this group. Silverstein 
et al101 reported encouraging results for hylan G-F 20 in the 
treatment of glenohumeral osteoarthritis. Their preliminary 
study of 20 patients, revealed significant improvements 
in VAS, University of California Los Angeles score, and 
Simple Shoulder Test scores (P  0.001) at the 6-month 
follow-up.
Finally, viscosupplementation for hand pain associated 
with osteoarthritis is currently under investigation. A recent 
prospective, randomized, double-blinded clinical trial 
compared hylan versus corticosteroid versus placebo for the 
treatment of basal joint arthritis.102 Sixty patients with basal 
joint arthritis were randomized to receive 2 intra-articular 
hylan injections 1 week apart, 1 placebo injection followed by 1 
corticosteroid injection 1 week later, or 2 placebo injections 
1 week apart. Patients were evaluated at 2, 4, 12 and 26 weeks 
and assessed with visual analog scale pain scores, strength 
measures, difference scores, Disabilities of the Arm, Shoulder, 
and Hand scores, and range of motion measurements. There 
were no statistically significant differences among hylan, 
steroid and placebo injections for most of the outcome 
measures at any of the follow-up time points. However, based 
on the durable relief of pain, improved grip strength, and the 
long-term improvement in symptoms compared with prein-
jection values, hylan injections should be considered in the 
management of basal joint arthritis of the thumb.
Conclusion
As a result of increased interest and scientific investigation 
of intra-articular viscosupplementation, its use in the non-
operative management of patients with osteoarthritis has 
become well accepted. In the case of hylan G-F 20, numer-
ous prospective, randomized, placebo-controlled studies 
have proven its efficacy. Cumulative evidence also affirms 
it clinical safety. Furthermore, recent data suggest that mul-
tiple courses of hylan G-F 20 are effective in maintaining 
osteoarthritis pain relief, and that this benefit outweighs 
the associated risk of adverse events. In addition, a single, 
higher dose of hylan G-F 20 may be just as effective as the 
traditional 3 injection regimen. Further clinical studies are 
necessary to prove the potential disease-modifying effects 
of hylan G-F 20. Viscosupplementation as a whole must 
expand beyond pain relief and joint preservation and evolve 
to encompass therapies that restore normal cartilage and 
joint homeostasis, arrest the progression of osteoarthritis, 
interfere with cartilage-degrading mechanisms, and reverse 
existing damage.96
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